KR20170020463A - Ezh2 저해제에의 반응에 대한 바이오마커 - Google Patents
Ezh2 저해제에의 반응에 대한 바이오마커 Download PDFInfo
- Publication number
- KR20170020463A KR20170020463A KR1020177001353A KR20177001353A KR20170020463A KR 20170020463 A KR20170020463 A KR 20170020463A KR 1020177001353 A KR1020177001353 A KR 1020177001353A KR 20177001353 A KR20177001353 A KR 20177001353A KR 20170020463 A KR20170020463 A KR 20170020463A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- bap1
- biomarker
- expression
- ezh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 161
- 239000003112 inhibitor Substances 0.000 title claims abstract description 65
- 230000004044 response Effects 0.000 title description 5
- 101150090105 Ezh2 gene Proteins 0.000 title description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 146
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 85
- 201000011510 cancer Diseases 0.000 claims abstract description 78
- 230000001093 anti-cancer Effects 0.000 claims abstract description 29
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 21
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract 19
- 210000004027 cell Anatomy 0.000 claims description 148
- 239000000523 sample Substances 0.000 claims description 85
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 101000966290 Homo sapiens Lethal(3)malignant brain tumor-like protein 2 Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 102100040546 Lethal(3)malignant brain tumor-like protein 2 Human genes 0.000 claims description 34
- 239000013643 reference control Substances 0.000 claims description 33
- 238000001262 western blot Methods 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 22
- 238000003752 polymerase chain reaction Methods 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 13
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 claims description 11
- 239000011324 bead Substances 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 10
- 238000002493 microarray Methods 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 230000001982 uveitic effect Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 201000003708 skin melanoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 210000002752 melanocyte Anatomy 0.000 claims description 5
- 206010027191 meningioma Diseases 0.000 claims description 5
- 201000008261 skin carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims 8
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims 8
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 claims 8
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 claims 8
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 3
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 230000000670 limiting effect Effects 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 33
- 230000003827 upregulation Effects 0.000 abstract description 5
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 description 146
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 145
- 102100037587 Ubiquitin carboxyl-terminal hydrolase BAP1 Human genes 0.000 description 135
- 101710138903 Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 134
- 101150054061 BAP1 gene Proteins 0.000 description 104
- 101150080421 MAGI1 gene Proteins 0.000 description 103
- 239000013615 primer Substances 0.000 description 69
- 102000053602 DNA Human genes 0.000 description 55
- 108020004414 DNA Proteins 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 46
- 108010033040 Histones Proteins 0.000 description 36
- 239000002243 precursor Substances 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 238000011529 RT qPCR Methods 0.000 description 19
- 238000012217 deletion Methods 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 206010027406 Mesothelioma Diseases 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 17
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 15
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 15
- 230000002950 deficient Effects 0.000 description 15
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 14
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 14
- 210000002798 bone marrow cell Anatomy 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- XQFINGFCBFHOPE-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl-[4-[2-methoxyethyl(methyl)amino]cyclohexyl]amino]-2-methyl-5-(3-morpholin-4-ylprop-1-ynyl)benzamide Chemical compound C=1C(C#CCN2CCOCC2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCC(N(C)CCOC)CC1 XQFINGFCBFHOPE-UHFFFAOYSA-N 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000011194 good manufacturing practice Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 9
- 102000006947 Histones Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 9
- 238000007451 chromatin immunoprecipitation sequencing Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 8
- 101001008816 Homo sapiens N-lysine methyltransferase KMT5A Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 102100027771 N-lysine methyltransferase KMT5A Human genes 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 101150084229 ATXN1 gene Proteins 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 210000003483 chromatin Anatomy 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 6
- 238000010199 gene set enrichment analysis Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101100218322 Arabidopsis thaliana ATXR3 gene Proteins 0.000 description 5
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 5
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 5
- 101100149326 Homo sapiens SETD2 gene Proteins 0.000 description 5
- 108700029495 HoxA Proteins 0.000 description 5
- 101150075146 L3MBTL2 gene Proteins 0.000 description 5
- 238000011789 NOD SCID mouse Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 101100533304 Plasmodium falciparum (isolate 3D7) SETVS gene Proteins 0.000 description 5
- 101150117538 Set2 gene Proteins 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- 102220519993 Ubiquitin carboxyl-terminal hydrolase BAP1_C91S_mutation Human genes 0.000 description 5
- 238000002679 ablation Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000004885 tandem mass spectrometry Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000003735 Mesothelin Human genes 0.000 description 4
- 108090000015 Mesothelin Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000242739 Renilla Species 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002924 silencing RNA Substances 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100036008 CD48 antigen Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 3
- 101001050320 Homo sapiens Junctional adhesion molecule B Proteins 0.000 description 3
- 101001051810 Homo sapiens MORC family CW-type zinc finger protein 3 Proteins 0.000 description 3
- 101001071230 Homo sapiens PHD finger protein 20 Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102100023430 Junctional adhesion molecule B Human genes 0.000 description 3
- 102100024822 MORC family CW-type zinc finger protein 3 Human genes 0.000 description 3
- 101100111224 Mus musculus Bap1 gene Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 102100036878 PHD finger protein 20 Human genes 0.000 description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 102000053093 human BAP1 Human genes 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101710196690 Actin B Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 238000001353 Chip-sequencing Methods 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700011215 E-Box Elements Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000017286 Histone H2A Human genes 0.000 description 2
- 108050005231 Histone H2A Proteins 0.000 description 2
- 102100033636 Histone H3.2 Human genes 0.000 description 2
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 2
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 2
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 description 2
- 101000866340 Homo sapiens Transcription factor E2F6 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100030355 Host cell factor 1 Human genes 0.000 description 2
- 108091010871 Host cell factor 1 Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 101100507912 Mus musculus Hoxa6 gene Proteins 0.000 description 2
- 101100178928 Mus musculus Hoxa9 gene Proteins 0.000 description 2
- 101100512246 Mus musculus Magi1 gene Proteins 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 2
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100031631 Transcription factor E2F6 Human genes 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102100031929 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Human genes 0.000 description 2
- 101710117112 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000001819 effect on gene Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 108091008147 housekeeping proteins Proteins 0.000 description 2
- 101150003074 hoxa5 gene Proteins 0.000 description 2
- 102000056255 human EZH2 Human genes 0.000 description 2
- 102000056054 human SUZ12 Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- -1 tetramethylpiperidinyl compound Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 description 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PFHDWRIVDDIFRP-UHFFFAOYSA-N 6-cyano-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide Chemical compound C1=C(C#N)C=C2N(C(CC)CC)C=CC2=C1C(=O)NCC1=C(C)C=C(C)NC1=O PFHDWRIVDDIFRP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710197940 Breast cancer type 1 susceptibility protein Proteins 0.000 description 1
- 102000014231 Breast cancer type 1 susceptibility protein (BRCA1) Human genes 0.000 description 1
- 108050003062 Breast cancer type 1 susceptibility protein (BRCA1) Proteins 0.000 description 1
- LXFOLMYKSYSZQS-LURJZOHASA-N CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 Chemical compound CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 LXFOLMYKSYSZQS-LURJZOHASA-N 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 241001313846 Calypso Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001014213 Homo sapiens Morphogenetic neuropeptide Proteins 0.000 description 1
- 101000728107 Homo sapiens Putative Polycomb group protein ASXL2 Proteins 0.000 description 1
- 101000728110 Homo sapiens Putative Polycomb group protein ASXL3 Proteins 0.000 description 1
- 101150012410 L3mbtl1 gene Proteins 0.000 description 1
- 101710173086 Lethal(3)malignant brain tumor-like protein 1 Proteins 0.000 description 1
- 102100030657 Lethal(3)malignant brain tumor-like protein 1 Human genes 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- LZHSWRWIMQRTOP-UHFFFAOYSA-N N-(furan-2-ylmethyl)-3-[4-[methyl(propyl)amino]-6-(trifluoromethyl)pyrimidin-2-yl]sulfanylpropanamide Chemical compound CCCN(C)C1=NC(=NC(=C1)C(F)(F)F)SCCC(=O)NCC2=CC=CO2 LZHSWRWIMQRTOP-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100029750 Putative Polycomb group protein ASXL2 Human genes 0.000 description 1
- 102100029749 Putative Polycomb group protein ASXL3 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100111225 Rattus norvegicus Bap1 gene Proteins 0.000 description 1
- 101100512247 Rattus norvegicus Magi1 gene Proteins 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- NZLIJGHPMIEDBX-UHFFFAOYSA-M azanium potassium hydrogen carbonate chloride Chemical compound [NH4+].[Cl-].[K+].OC([O-])=O NZLIJGHPMIEDBX-UHFFFAOYSA-M 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BXLNWOAYQXBHCY-UHFFFAOYSA-N diphenylsilylidene(diphenyl)silane Chemical compound C1=CC=CC=C1[Si](C=1C=CC=CC=1)=[Si](C=1C=CC=CC=1)C1=CC=CC=C1 BXLNWOAYQXBHCY-UHFFFAOYSA-N 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000027858 endometrioid tumor Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 102000048436 human L3MBTL2 Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 1
- DPJNKUOXBZSZAI-UHFFFAOYSA-N n-[(6-methyl-2-oxo-4-propyl-1h-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=NC(=CC=2)N2CCN(CC2)C(C)C)C(C)C)=C1CCC DPJNKUOXBZSZAI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
- G01N2333/91011—Methyltransferases (general) (2.1.1.)
- G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014594P | 2014-06-19 | 2014-06-19 | |
| US62/014,594 | 2014-06-19 | ||
| PCT/US2015/036677 WO2015196064A1 (en) | 2014-06-19 | 2015-06-19 | Biomarkers for response to ezh2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170020463A true KR20170020463A (ko) | 2017-02-22 |
Family
ID=54936135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177001353A Abandoned KR20170020463A (ko) | 2014-06-19 | 2015-06-19 | Ezh2 저해제에의 반응에 대한 바이오마커 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170138946A1 (enExample) |
| EP (1) | EP3158086B1 (enExample) |
| JP (1) | JP6684230B2 (enExample) |
| KR (1) | KR20170020463A (enExample) |
| CN (1) | CN106795561B (enExample) |
| AU (1) | AU2015276899B2 (enExample) |
| BR (1) | BR112016029911A2 (enExample) |
| CA (1) | CA2952285A1 (enExample) |
| EA (1) | EA036889B1 (enExample) |
| ES (1) | ES2870096T3 (enExample) |
| IL (1) | IL249443B (enExample) |
| MX (1) | MX384423B (enExample) |
| SG (2) | SG10202007972SA (enExample) |
| WO (1) | WO2015196064A1 (enExample) |
| ZA (1) | ZA201608555B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US12442042B2 (en) | 2016-02-16 | 2025-10-14 | Agency For Science, Technology And Research | Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma |
| GB201615842D0 (en) * | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| WO2020247130A1 (en) * | 2019-06-03 | 2020-12-10 | Icahn School Of Medicine At Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN118161615B (zh) * | 2024-03-19 | 2025-08-12 | 山东大学齐鲁医院 | Phf20抑制剂在制备抗皮肤癌药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US548257A (en) | 1895-10-22 | Hay rake and loader | ||
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US5932422A (en) * | 1997-11-14 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
| US6218114B1 (en) | 1998-03-27 | 2001-04-17 | Academia Sinica | Methods for detecting differentially expressed genes |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| WO2001055454A1 (en) | 2000-01-28 | 2001-08-02 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| EP1385998A1 (en) | 2001-04-19 | 2004-02-04 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
| AU2001286171B2 (en) | 2001-05-25 | 2008-01-10 | Serono Genetics Institute S.A. | Human CDNAs and proteins and uses thereof |
| US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| EP1425695A2 (en) | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
| AU2003213054A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
| WO2003091735A1 (en) | 2002-04-23 | 2003-11-06 | Millipore Corporation | Sample preparation of biological fluids for proteomic applications |
| WO2007001986A2 (en) | 2005-06-20 | 2007-01-04 | Yuling Luo | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20140011696A1 (en) * | 2011-02-16 | 2014-01-09 | Thomas Wiesner | Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia |
| WO2012144220A1 (en) * | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
| BR112014007603A2 (pt) * | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| EP2825161B1 (en) | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
-
2015
- 2015-06-19 MX MX2016017097A patent/MX384423B/es unknown
- 2015-06-19 CN CN201580044280.9A patent/CN106795561B/zh not_active Expired - Fee Related
- 2015-06-19 EP EP15809484.7A patent/EP3158086B1/en active Active
- 2015-06-19 EA EA201692497A patent/EA036889B1/ru unknown
- 2015-06-19 SG SG10202007972SA patent/SG10202007972SA/en unknown
- 2015-06-19 BR BR112016029911A patent/BR112016029911A2/pt not_active Application Discontinuation
- 2015-06-19 AU AU2015276899A patent/AU2015276899B2/en not_active Ceased
- 2015-06-19 CA CA2952285A patent/CA2952285A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036677 patent/WO2015196064A1/en not_active Ceased
- 2015-06-19 SG SG11201610610YA patent/SG11201610610YA/en unknown
- 2015-06-19 ES ES15809484T patent/ES2870096T3/es active Active
- 2015-06-19 JP JP2016573588A patent/JP6684230B2/ja not_active Expired - Fee Related
- 2015-06-19 KR KR1020177001353A patent/KR20170020463A/ko not_active Abandoned
-
2016
- 2016-12-07 IL IL249443A patent/IL249443B/en unknown
- 2016-12-12 ZA ZA2016/08555A patent/ZA201608555B/en unknown
- 2016-12-15 US US15/380,807 patent/US20170138946A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015276899A1 (en) | 2017-01-05 |
| JP2017525337A (ja) | 2017-09-07 |
| CN106795561A (zh) | 2017-05-31 |
| EP3158086A4 (en) | 2018-01-10 |
| ZA201608555B (en) | 2022-05-25 |
| WO2015196064A1 (en) | 2015-12-23 |
| CA2952285A1 (en) | 2015-12-23 |
| CN106795561B (zh) | 2021-04-16 |
| BR112016029911A2 (pt) | 2017-10-24 |
| JP6684230B2 (ja) | 2020-04-22 |
| AU2015276899B2 (en) | 2021-08-12 |
| EA201692497A1 (ru) | 2017-06-30 |
| EA036889B1 (ru) | 2021-01-12 |
| IL249443B (en) | 2022-05-01 |
| SG11201610610YA (en) | 2017-01-27 |
| US20170138946A1 (en) | 2017-05-18 |
| ES2870096T3 (es) | 2021-10-26 |
| IL249443A0 (en) | 2017-02-28 |
| MX384423B (es) | 2025-03-14 |
| MX2016017097A (es) | 2017-05-01 |
| EP3158086B1 (en) | 2021-03-24 |
| SG10202007972SA (en) | 2020-10-29 |
| EP3158086A1 (en) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fan et al. | CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer | |
| JP6684230B2 (ja) | Ｅｚｈ２阻害剤への応答についてのバイオマーカー | |
| Song et al. | Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression | |
| Choi et al. | YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC | |
| LaFave et al. | Loss of BAP1 function leads to EZH2-dependent transformation | |
| Shang et al. | ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer | |
| CN103026227B (zh) | 新的卵巢癌生物标志物和靶 | |
| Li et al. | UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β‐catenin signaling | |
| Khammanivong et al. | Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC | |
| Di Maira et al. | Oncostatin M is overexpressed in NASH‐related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis | |
| Huang et al. | DDB2 is a novel regulator of Wnt signaling in colon cancer | |
| US11707481B2 (en) | Compositions and methods of treating Fanconi Anemia | |
| Shen et al. | ALKBH4 functions as a suppressor of colorectal cancer metastasis via competitively binding to WDR5 | |
| Chen et al. | CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway | |
| Li et al. | BMP suppresses Wnt signaling via the Bcl11b-regulated NuRD complex to maintain intestinal stem cells | |
| Ma et al. | Tumor suppressor FRMD3 controls mammary epithelial cell fate determination via notch signaling pathway | |
| St-Laurent Pedneault et al. | Regulated expression of a FANCL splicing variant as a potential modifier of DNA repair activity | |
| HK1230671B (en) | Biomarkers for response to ezh2 inhibitors | |
| Raju et al. | NFAT2 drives both Orai3 transcription and protein degradation by harnessing the differences in epigenetic landscape of MARCH8 E3 ligase | |
| Lv et al. | Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC | |
| Singh et al. | Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity | |
| Wang | Role of SETD2 in Kidney Cancer Progression | |
| Liu | EZH2 Plays Distinct Roles in Tumor Initiation and Metastasis in Breast Cancer | |
| Zolghadri et al. | GNA15 signaling facilitates the initial phases of pancreas cell transformation and is associated with the basal-like/squamous subtype | |
| Sun et al. | SPC25 upregulates CCND1 to promote the progression of esophageal squamous cell carcinoma by MDM2-mediated E2F1 ubiquitination and stabilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170116 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200619 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210716 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220217 |
|
| PC1904 | Unpaid initial registration fee |